Welcome to our dedicated page for Inotiv news (Ticker: NOTV), a resource for investors and traders seeking the latest updates and insights on Inotiv stock.
Inotiv, Inc. reports news as a contract research organization providing nonclinical and analytical drug discovery and development services, research models, and related products for pharmaceutical, chemical, medical device, and biomedical research customers. Its updates commonly address Discovery and Safety Assessment activity, Research Models and Services performance, quarterly and annual financial results, and business trends tied to discovery, preclinical, and translational research demand.
Company announcements also cover collaborations and technology additions such as human-relevant in vitro models, AI-assisted bioinformatics, and multi-omics analysis within Discovery & Translational Sciences. Other recurring items include conference-call schedules, operational business updates, cybersecurity incident notices, and corporate communications affecting Nasdaq-listed common stock.
Inotiv, Inc. (NASDAQ: NOTV) reported a significant 370.4% revenue increase for Q1 FY 2022, totaling $84.2 million, compared to $17.9 million in Q1 FY 2021. This growth was driven by acquisitions and internal growth. However, the company recorded a net loss of $83.0 million, or $(3.93) per share, reflecting increased operating expenses, including $23.0 million in stock compensation due to acquisitions. Adjusted EBITDA rose to $10.1 million, up 621.4%. DSA backlog increased 130.9% to $104.6 million, indicating robust future revenue prospects.
Inotiv, Inc. (NASDAQ: NOTV) will release its financial results for the fiscal 2022 first quarter, ending December 31, 2021, on February 10, 2022, after market close. The Company will host a conference call at 4:30 p.m. ET on the same day for discussion of the results. Interested participants can join via domestic and international dialing options. The live webcast will be accessible on the Investors section of Inotiv's website, with a replay available post-broadcast. Inotiv specializes in drug discovery and development services, focusing on improving efficiency and reducing costs in bringing new drugs to market.
Inotiv (NASDAQ: NOTV) has acquired Orient BioResource Center (OBRC) for $51.3 million, including $28.3 million in cash and approximately 677,339 shares valued at $23.0 million. The acquisition aims to enhance Inotiv's capabilities by integrating OBRC's primate facility in Alice, Texas, which spans 500 acres and generated $23 million in revenue in fiscal 2021. This strategic move seeks to fulfill client demands for increased research model access while maintaining high animal welfare standards.
Inotiv, Inc. (NASDAQ: NOTV) announced the acquisition of Integrated Laboratory Systems, LLC (ILS) for $56 million, comprising $38 million in cash and 429,118 shares valued at $18 million. ILS, specializing in genetic toxicology and related services, reported $20 million in revenue for 2021. This acquisition enhances Inotiv's capacity in toxicology services and extends its expertise into genomics and bioinformatics. The addition of ILS is anticipated to broaden Inotiv's market reach and create significant cross-selling opportunities, retaining all existing ILS employees.
Inotiv, Inc. (NASDAQ: NOTV) has announced the acquisition of the rabbit breeding and supply business from Robinson Services Inc. (RSI). This move aims to enhance Inotiv's Research Models and Services (RMS) sector by consolidating RSI's assets, including its customer list and a supply agreement for rabbits. The acquisition is expected to optimize Inotiv’s global footprint and offer a wider range of options for clients. Inotiv plans to integrate RSI's operations into its existing facilities throughout 2022, positioning itself for future growth in the research and drug development markets.
Inotiv, Inc. (NASDAQ: NOTV) and Synexa Life Sciences announced a strategic collaboration aimed at enhancing the development of biotherapeutics through advanced biomarker analysis. This partnership is expected to broaden Inotiv's service offerings, enhance customer reach, and create cost and revenue synergies. Synexa will establish U.S. operations at Inotiv's Rockville, MD facility, supporting the development of GLP-compliant biomarker services. The collaboration aims to simplify outsourcing for biopharmaceutical companies and foster preferred provider partnerships in an increasingly complex drug development landscape.
Inotiv, Inc. (NASDAQ: NOTV) reported significant growth in Q4 and FY 2021. Q4 revenue surged by 90.7% to $30.1 million, driven by acquisitions and internal growth, while FY 2021 revenue increased 48.2% to $89.6 million. Net income for Q4 reached $9.4 million compared to a net loss of $(1.8) million in Q4 2020, aided by PPP loan forgiveness. Operating expenses rose 128.8% in Q4 due to strategic investments. The company reported a backlog of $81.4 million by quarter-end, indicating strong future revenue potential.
Inotiv, Inc. (NASDAQ: NOTV) will release its financial results for Q4 fiscal 2021, ending September 30, 2021, on December 16, 2021, after market close. A conference call will follow at 4:30 p.m. ET to discuss the results. Participants can join by calling (877) 407-9753 (domestic) or (201) 493-6739 (international). The call will be accessible via the company's website, with a replay available post-broadcast. Inotiv specializes in nonclinical and analytical drug discovery, aiming to enhance efficiency and reduce costs in bringing new drugs to market.
Inotiv, Inc. (NASDAQ: NOTV) has launched new transgenic rodent models tailored for SARS-CoV-2 research. These models, developed by its RMS business and the recently acquired Envigo, include a mouse model with human ACE2 and TMPRSS2 genes, and a rat model with human ACE2. Designed to address the limitations of existing models, Inotiv's new offerings enable more accurate studies of COVID-19 and associated treatments. Utilizing CRISPR technology, the models mimic human disease pathologies closely, enhancing research capabilities for vaccine and drug testing.
Inotiv, Inc. (NASDAQ: NOTV) announces preliminary unaudited financial results for Q4 and FY 2021, reporting a substantial revenue increase. Q4 FY 2021 revenue reached $30.1 million, marking a 90.7% rise from Q4 FY 2020. Gross profit for the same period was $10.3 million, up 123.0%. For FY 2021, total revenue was $89.6 million, a 48.2% increase. The company also reported a backlog of $81.4 million, reflecting strong business growth. The earnings call to discuss these results will be rescheduled due to ongoing audit work.